Select Scientific Publications
-
-
-
Cell Discovery
-
-
-
Company Activities & Updates
AACR AI&ML Award
September 17, 2025
ExoMira team members received AACR’s Top Poster Award for applying deep learning to characterize immune tumor ecosystems for prognostic cancer assessment.
Innovation Award
June 4, 2025
Drs. Fang and Liu were awarded a Lurie Cancer Center Research Innovation Challenge Award to advance USP22 inhibitor development toward clinical trial readiness.
AAI Involvement
May 10, 2025
Dr. Deyu Fang moderated a leading tumor immunology session at the 2025 AAI Annual Meeting, showcasing ExoMira’s continued impact in the cancer immunotherapy space.
FASEB Presentation
May 7, 2025
Dr. Huiping Liu gave an invited talk on CTC cluster plasticity and immune evasion at the 2025 FASEB Cancer Conference in Hong Kong, reinforcing ExoMira’s scientific leadership.
SBIR Top Score
March 20, 2025
ExoMira receives an outstanding fundable score on a highly competitive SBIR grant, positioning the company for future scale-up toward clinical trials.
New Appointment
March 10, 2025
ExoMira appoints Yan He as Director of Business & Clinical Development, strengthening its business development, clinical, and regulatory leadership as ExoMira advances toward first-in-human studies.